Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 17/20 | 0.68 |
| ▸ | HTR2A | P28223 | 4/20 | 0.68 |
| ▸ | DRD3 | P35462 | 14/20 | 0.67 |
| ▸ | DRD4 | P21917 | 7/20 | 0.60 |
| ▸ | FAAH | O00519 | 1/20 | 0.60 |
| ▸ | CNR1 | P21554 | 1/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.60 |
| ▸ | HTR1A | P08908 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3162949 | 0.92 | DRD2 (0.69) | DRD2HTR2ADRD3DRD4FAAH | |
| SCHEMBL3187864 | 0.89 | DRD2 (0.67) | DRD2HTR2ADRD3DRD4FAAH | |
| Hydrochloric Acid SCHEMBL3207599 | 0.88 | DRD2 (0.65) | DRD2HTR2ADRD3DRD4FAAH | |
| SCHEMBL19580065 | 0.83 | DRD3 (0.73) | DRD2HTR2ADRD3DRD4FAAH | |
| SCHEMBL1193607 | 0.83 | DRD2 (0.83) | DRD2HTR2ADRD3DRD4SLC6A2 | |
| SCHEMBL1491174 | 0.83 | DRD2 (0.65) | DRD2HTR2ADRD3DRD4FAAH | |
| SCHEMBL19580027 | 0.82 | DRD3 (0.79) | DRD2DRD3DRD4FAAHCNR1 | |
| SCHEMBL1193610 | 0.82 | DRD2 (0.81) | DRD2HTR2ADRD3DRD4SLC6A2 | |
| Hydrochloric Acid SCHEMBL5366724 | 0.82 | DRD2 (0.81) | DRD2HTR2ADRD3DRD4SLC6A2 | |
| SCHEMBL14494878 | 0.81 | DRD2 (0.76) | DRD2HTR2ADRD3DRD4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207163-B2 | Compositions, synthesis, and methods of using piperazine based antipsychotic agents | REVIVA PHARMACEUTICALS, INC. (US) | 2012-06-26 | — | — | US | disclosed |
| EP-2299814-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PIPERAZINE BASED ANTIPSYCHOTIC AGENTS | Reviva Pharmaceuticals, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009154993-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PIPERAZINE BASED ANTIPSYCHOTIC AGENTS | REVIVA PHARMACEUTICALS, INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| US-20090298819-A1 | Compositions, Synthesis, And Methods Of Using Piperazine Based Antipsychotic Agents | REVIVA PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298819-A1 | Compositions, Synthesis, And Methods Of Using Piperazine Based Antipsychotic Agents | GRIK5, GAP43, GRIN2D | DRD2 33/4885HTR2A 41/4885DRD3 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.